NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Cronos Group Inc. (CRON) Stock Analysis

Cronos Group Inc. (CRON) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

CRON

$3.26

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRON with… →

CRON Key Statistics

As of Sep 4, 2026
Trading
Open
$3.22
Previous Close
$3.26
Day's Range
3.22–3.27
52-Week Range
2.28–3.61
Volume
493.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.28
Valuation
Market Cap
$1.20B
P/E Ratio
17.16
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.71
EPS (ttm)Profit attributable to each share over the last twelve months.
0.19
Financials (FY)
Revenue (FY)
$146.59M+24.63%
Net Income (FY)
−$9.45M−123.00%
Profit marginThe share of revenue left as profit after all costs and taxes.
39.08%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
368.41M
1-Year Return
+30.40%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.19M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CRON Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+23.95%
2025+30.20%
2024−3.35%
2023−17.72%
2022−35.20%
2021−43.52%
2020−9.52%
2019−26.18%
2018 (partial year)+36.35%

As of September 4, 2026.

CRON Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$146.59M−$9.45M−6.4%
2024$117.62M$41.08M34.9%
2023$87.24M−$73.96M−84.8%
2022$86.75M−$168.73M−194.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$146.59M$62.76M−$19.50M−$9.45M−6.4%
2024$117.62M$25.20M−$59.55M$41.08M34.9%
2023$87.24M$11.91M−$79.91M−$73.96M−84.8%
2022$86.75M$15.44M−$104.39M−$168.73M−194.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRON Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricCRONDrug Manufacturers - Specialty & Generic medianvs median
P/E17.1619.2711% below
P/S ratio6.712.30192% above
Profit margin39.08%−3.14%42.2 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cronos Group Inc. (CRON) carries a market capitalisation of $1.20B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 610 employees.

Over the past 52 weeks the price has ranged from $2.28 to $3.61. CRON last closed at $3.26 on September 4, 2026. The close was unchanged from the previous session. The latest close sits 42.98% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $146.59M. Against the prior fiscal year total of $117.62M, that is a change of +24.63%. The same year closed with a net loss of $9.45M. The reported profit margin is 39.08%. That is 42.2 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to 0.19.

Across the 4 fiscal years on file, revenue moves from $86.75M in 2022 to $146.59M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 17.16. That is 10.93% below the Drug Manufacturers - Specialty & Generic median of 19.27. Measured against sales, the shares trade at 6.71 times revenue. On price-to-sales that is 192.05% above the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the price has returned +30.40%. Across 5 years the annualized return works out at −12.89%. Beta against the wider market is reported at 1.28. Daily returns over the trailing 8 years annualize to a volatility of 63.12%.

Growth & Income

No dividend is on file for CRON.

Across the complete calendar years on file, 2025 returned +30.20% and 2021 returned −43.52%. Of the 7 complete calendar years on file, 1 finished higher. So far in 2026 the price is +23.95%.

Peer Comparison

Cronos Group Inc. (CRON) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cronos Group Inc. CRON $1.20B 17.2
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Cronos Group Inc. trades at a P/E of 17.2.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cronos Group Inc.

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.

Visit website →